
Cat. #153688
Anti-Cryptococcus [crp127]
Cat. #: 153688
Unit size: 100 ug
Availability: 3-4 weeks
Target: Cryptococcus
Class: Monoclonal
Application: IF ; WB
Reactivity: Cryptococcus gatti; Cryptococcus neoformans
Host: BALB/c Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Robin May
Institute: University of Birmingham
Primary Citation: Probert et al. 2019. Infect Immun. 87(4):e00731-18. PMID: 30670549
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-Cryptococcus [crp127]
- Alternate name: Cryptococcal capsule, Filobasidiella
- Research fields: Microbiology
- Class: Monoclonal
- Conjugation: Unconjugated
- Reactivity: Cryptococcus gatti; Cryptococcus neoformans
- Host: BALB/c Mouse
- Application: IF ; WB
- Description: Cryptococcus is a genus of environmental fungi, with most species commonly found in soil. Pathogenic members of this genus, particularly Cryptococcus neoformans and Cryptococcus gattii, are encapsulated by a gelatinous layer composed of capsular glycoproteins. This capsule plays a key role in nutrient acquisition and immune evasion. The capsule of C. neoformans, the most prominent human and animal pathogen in the genus, is distinguished by a high content of glucuronic acid and mannose residues, including O-acetyl groups, which contribute to its function as a major virulence factor. Monoclonal antibody Crp127 (clone 127) specifically recognizes capsular material on the surface of C. neoformans and C. gattii but does not bind to the capsule of the related species C. laurentii. Antigen recognition by Crp127 appears to be dependent on the presence of O-acetylation within the capsular polysaccharide.
- Immunogen: Heat-killed cells and lysate of C. neoformans H99 (serotype A) and C. gattii R265 (serotype B)
- Isotype: IgM
- Production details: Monoclonal antibody Crp127 (clone 127) was generated by immunizing BALB/c mice with a mixture of heat-killed and lysed Cryptococcus neoformans H99 and Cryptococcus gattii R265 cells. Fungal cultures were heat-inactivated at 65°C for 60 minutes, confirmed non-viable by plating, and mechanically lysed using bead-based disruption. Following hyperimmunization, splenocytes were harvested and fused with NS0 myeloma cells using polyethylene glycol to produce hybridomas. Screening of hybridoma supernatants was performed via epifluorescence microscopy using FITC-conjugated anti-mouse IgG and IgM antibodies to identify reactive clones. Clone 127 was selected for its specificity and cultured in RPMI 1640 supplemented with IgG-depleted FBS.
- Myeloma used: NS0
Target Details
- Target: Cryptococcus
- Target background: Cryptococcus is a genus of fungus of where the majority of organisms are found living in the soil. Cryptococcal cells are covered in a thin gelatin-like layer of capsular glycoprotein material which serves to help extract nutrients from the surroundings. The capsule from C. neoformans which is the most prominent human and animal pathogen in the genus, is different. Its capsule has a greater composition of glucuronic acid and mannose possessing O-acetyl groups and functions as the major virulence factor contributing to cryptococcal infection and disease. The antibody recognises capsular material on the surface of the pathogenic fungi Cryptococcus gattii and C. neoformans. It does not appear to recognise the capsule on the related species C. laurentii and recognition appears to depend on O-acetylation of the capsular polysaccharide.
Applications
- Application: IF ; WB
Handling
- Format: Liquid
- Concentration: 1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: Product stable at -20°C when stored undiluted. Avoid repeated freeze-thaw cycles.
- Shipping conditions: Dry ice
References
- Probert et al. 2019. Infect Immun. 87(4):e00731-18. PMID: 30670549
![Anti-CAR Whitlow Linker [1C3C3]](https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-300x322.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-280x300.jpg 280w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-954x1024.jpg 954w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-768x824.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 1193w)

![Anti-CAR Whitlow Linker [1B4A1]](https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-300x396.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-227x300.jpg 227w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-776x1024.jpg 776w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-768x1013.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 970w)




